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The main aims of this study were to investigate the combined effects of a natural 
compound 1’S-1’-acetoxychavicol acetate (ACA) with cisplatin (CDDP) on human 
cervical carcinoma cells Ca Ski, and to identify microRNAs (miRNAs) asscociated with 
response towards ACA and/or CDDP. Data obtained from MTT cell viability assays 
indicated that both ACA and CDDP induced dose- and time-dependent cytotoxicity on 
Ca Ski cells when used as a standalone agent. The in vitro studies also demonstrated 
that ACA potentiates the cytotoxic effects of CDDP when used in combination through 
synergistic interactions. The miRNA microarray was used to identify global miRNA 
expression profiles on Ca Ski cells following administration of ACA and/or CDDP, and 
it was found that 25 miRNAs were differentially expressed in response towards ACA 
and/or CDDP with markedly different pattern of miRNA expressions between different 
treatment regimens. Three promising miRNA candidates (hsa-miR-138, hsa-miR-210 
and hsa-miR-744) which exhibited the highest fold-change in combination 
chemotherapy and whose expressions were among those validated by qRT-PCR, were 
selected for bioinformatic analyses. The hypothetical pathway model comprising 
interaction between candidate miRNAs with their putative target genes indicated that 
the cytotoxic effects induced by ACA in combination with CDDP may be regulated by 
miRNA expression. Therefore, our study provides a platform for potential therapeutic 
approaches in chemotherapy, whereby miRNA expression can be exploited to further 








Tujuan utama penyelidikan ini adalah untuk menyiasat kesan gabungan 
kompaun semulajadi 1’S-1’-acetoxychavicol acetate (ACA) dengan cisplatin (CDDP) 
ke atas sel-sel karsinoma serviks manusia Ca Ski, serta mengenal pasti miRNA yang 
bertindak balas terhadap rawatan ACA dan/atau CDDP. Data yang diperolehi daripada 
eksperimen MTT menunjukkan bahawa ACA dan CDDP menyebabkan sitotosik yang 
bergantung pada dos dan tempoh rawatan apabila digunakan sebagai ejen ‘standalone’. 
Selain itu, kajian in vitro juga menunjukkan bahawa ACA mempotensikan kesan 
sitotoksik CDDP melalui hubungan sinergistik apabila digabungkan. MiRNA 
microarray digunakan untuk mengenal pasti profil ekspresi global miRNA setelah 
dirawat dengan ACA dan/atau CDDP, dan didapati bahawa terdapat sebanyak 25 
miRNA yang diekspreskan secara berlainan apabila dirawat dengan ACA dan/atau 
CDDP dengan corak ekspresi miRNA yang berbeza antara regimen rawatan yang 
berlainan. Tiga calon miRNA yang menjanjikan (hsa-miR-138, hsa-miR-210 and hsa-
miR-744), yang merupakan antara beberapa miRNA yang disahkan ekspresinya dengan 
qRT-PCR, dipilih untuk analisis bioinformatik kerana mereka mempamerkan ‘fold-
change’ yang paling tinggi dalam kemoterapi kombinasi. ‘Hypothetical pathway model’ 
yang melibatkan interaksi miRNA dengan target gen putatif miRNA menunjukkan 
bahawa kesan-kesan sitotoksik yang ditunjukkan oleh ACA dan/atau CDDP 
berkemungkinan besar disebabkan oleh ekspresi miRNA. Maka, kajian kami 
menyediakan satu platform bagi pendekatan terapeutik dalam kemoterapi, dimana 
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